Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
NMTC1
MCID: THY109
MIFTS: 60

Thyroid Cancer, Nonmedullary, 1 (NMTC1)

Categories: Cancer diseases, Endocrine diseases, Genetic diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Thyroid Cancer, Nonmedullary, 1

About this section

MalaCards integrated aliases for Thyroid Cancer, Nonmedullary, 1:

Name: Thyroid Cancer, Nonmedullary, 1 58
Papillary Thyroid Carcinoma 12 54 30 6 15 17 74
Familial Nonmedullary Thyroid Cancer, Papillary 58 54 76
Nonmedullary Thyroid Carcinoma, Papillary 58 54 76
Non-Medullary Thyroid Carcinoma 76 74
Papillary Carcinoma of Thyroid 58 76
Thyroid Carcinoma, Papillary 77 13
Nmtc1 58 76
Pact 58 76
Papillary Carcinoma of Thyroid; Pact; Ptc; Tpc 58
Familial Nonmedullary Thyroid Gland Carcinoma 74
Papillary Carcinoma of the Thyroid Gland 12
Familial Non-Medullary Thyroid Cancer 76
Cancer, Thyroid, Nonmedullary, Type 1 41
Thyroid Carcinoma, Nonmedullary, 1 13
Thyroid Carcinoma, Nonmedullary 1 74
Thyroid Cancer, Non-Medullary, 1 76
Nonmedullary Thyroid Carcinoma 1 6
Nonmedullary Thyroid Carcinoma 76
Cancer, Thyroid, Nonmedullary 41
Thyroid Papillary Carcinoma 56
Papillary Thyroid Cancer 56
Fnmtc 76
Nmtc 76
Ptc 76
Tpc 76

Characteristics:

OMIM:

58
Inheritance:
autosomal dominant


HPO:

33
thyroid cancer, nonmedullary, 1:
Inheritance autosomal dominant inheritance


Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases Cancer diseases
Anatomical: Endocrine diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:3969
OMIM 58 188550
NCIt 51 C4035
SNOMED-CT 69 4797003
MedGen 43 C0238463
SNOMED-CT via HPO 70 255029007 263681008 3716002
Sources

Summaries for Thyroid Cancer, Nonmedullary, 1

About this section
OMIM : 58 Nonmedullary thyroid cancer (NMTC) comprises thyroid cancers of follicular cell origin and accounts for more than 95% of all thyroid cancer cases. The remaining cancers originate from parafollicular cells (medullary thyroid cancer, MTC; 155240). NMTC is classified into 4 groups: papillary, follicular (188470), Hurthle cell (607464), and anaplastic. Approximately 5% of NMTC is hereditary, occurring as a component of a familial cancer syndrome (e.g., familial adenomatous polyposis, 175100; Carney complex, 160980) or as a primary feature (familial NMTC or FNMTC). Papillary thyroid cancer (PTC) is the most common histologic subtype of FNMTC, accounting for approximately 85% of cases (summary by Vriens et al., 2009). PTC is characterized by distinctive nuclear alterations including pseudoinclusions, grooves, and chromatin clearing. PTCs smaller than 1 cm are referred to as papillary microcarcinomas. These tumors have been identified in up to 35% of individuals at autopsy, suggesting that they may be extremely common although rarely clinically relevant. PTC can also be multifocal but is typically slow-growing with a tendency to spread to lymph nodes and usually has an excellent prognosis (summary by Bonora et al., 2010). (188550)

MalaCards based summary : Thyroid Cancer, Nonmedullary, 1, also known as papillary thyroid carcinoma, is related to struma ovarii and differentiated thyroid carcinoma. An important gene associated with Thyroid Cancer, Nonmedullary, 1 is NKX2-1 (NK2 Homeobox 1), and among its related pathways/superpathways are Cell Differentiation - Index and miRs in Muscle Cell Differentiation. The drugs Iodine and Anti-Infective Agents, Local have been mentioned in the context of this disorder. Affiliated tissues include thyroid, lymph node and endothelial, and related phenotypes are goiter and papillary thyroid carcinoma

Disease Ontology : 12 A thyroid carcinoma that is characterized by the small mushroom shape of the tumor which has a stem attached to the epithelial layer.

NIH Rare Diseases : 54 Papillary thyroid carcinoma is a form of cancer that occurs due to abnormal and uncontrolled cell growth of certain cells (follicular cells) of the thyroid. Many people with papillary thyroid carcinoma have no signs or symptoms of the condition. When present, symptoms may include a small lump at the base of the neck, hoarseness, difficulty swallowing, trouble breathing, and pain in the neck or throat. Although people of all ages may be diagnosed with the condition, women between ages 30 and 50 are most commonly affected. The cause of papillary thyroid carcinoma is currently unknown. Risks for developing thyroid cancer include a history of high-dose external radiation treatments to the neck and radiation exposure during nuclear plant disasters. The best treatment options depend on many factors, but may include surgery, radiation therapy (including radioactive iodine therapy), chemotherapy and thyroid hormone therapy.

UniProtKB/Swiss-Prot : 76 Thyroid cancer, non-medullary, 1: A form of non-medullary thyroid cancer (NMTC), a cancer characterized by tumors originating from the thyroid follicular cells. NMTCs represent approximately 95% of all cases of thyroid cancer and are classified into papillary, follicular, Hurthle cell, and anaplastic neoplasms.

Wikipedia : 77 Papillary thyroid cancer or papillary thyroid carcinoma is the most common type of thyroid cancer,... more...

Sources

Related Diseases for Thyroid Cancer, Nonmedullary, 1

About this section

Diseases in the Thyroid Cancer, Nonmedullary, 2 family:

Thyroid Cancer, Nonmedullary, 1 Thyroid Cancer, Nonmedullary, 3
Thyroid Cancer, Nonmedullary, 4 Thyroid Cancer, Nonmedullary, 5

Diseases related to Thyroid Cancer, Nonmedullary, 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 331)
# Related Disease Score Top Affiliating Genes
1 struma ovarii 31.5 BRAF NKX2-1
2 differentiated thyroid carcinoma 31.1 BRAF GAS8-AS1 NKX2-1
3 thyroid cancer 31.0 BRAF GAS5 HOTAIR NKX2-1 PTCSC3
4 lung cancer susceptibility 3 30.9 BRAF GAS5 HOTAIR LINC-ROR NKX2-1
5 dermatomyositis 30.8 MIR221 MIR222
6 melanoma 30.8 MIR222 MIR221 LINC-ROR HOTAIR GAS5 BRAF
7 diffuse large b-cell lymphoma 30.6 HOTAIR HULC MIR221
8 papillary thyroid microcarcinoma 30.6 BRAF NKX2-1
9 ovarian cancer 30.4 BRAF GAS5 HOTAIR LINC-ROR MIR146A MIR221
10 squamous cell carcinoma, head and neck 30.4 BRAF GAS5 HOTAIR MIR221
11 prostate cancer 30.4 GAS5 HOTAIR HOTTIP HULC MIR146A MIR221
12 renal cell carcinoma, nonpapillary 30.4 GAS5 HOTAIR LINC-ROR NKX2-1
13 glioblastoma 30.3 PTCSC2 MIR222 MIR221 HOTAIR GAS5 BRAF
14 bladder cancer 30.3 BANCR GAS5 HOTAIR HULC MIR221 MIR222
15 esophageal cancer 30.3 GAS5 HOTAIR HOTTIP HULC LINC-ROR
16 pancreatic cancer 30.1 MIR222 MIR221 MIR146A LINC-ROR HULC HOTTIP
17 glioma 30.1 PTCSC3 MIR222 MIR221 HULC HOTTIP HOTAIR
18 hepatocellular carcinoma 30.0 MIR222 MIR221 MIR146A LINC-ROR HULC HOTTIP
19 gastric cancer 30.0 MIR222 MIR221 LINC-ROR HULC HOTTIP HOTAIR
20 colorectal cancer 29.8 BANCR BRAF GAS5 HOTAIR HOTTIP HULC
21 multicentric papillary thyroid carcinoma 12.4
22 thyroid cancer, nonmedullary, 3 11.6
23 thiourea tasting 11.5
24 thyroid carcinoma, papillary, with papillary renal neoplasia 11.4
25 thyroid carcinoma, nonmedullary, with or without cell oxyphilia 11.2
26 familial papillary or follicular thyroid carcinoma 11.1
27 thyroid cancer, nonmedullary, 2 11.1
28 thyroid cancer, nonmedullary, 4 11.1
29 thyroid cancer, nonmedullary, 5 11.1
30 papillary carcinoma 10.8
31 hashimoto thyroiditis 10.6
32 esophagus squamous cell carcinoma 10.5 BANCR HOTAIR
33 triple-receptor negative breast cancer 10.5 HOTAIR LINC-ROR
34 ovarian epithelial cancer 10.5 HOTAIR HULC
35 malignant glioma 10.5 GAS5 HOTAIR HOTTIP
36 coronary heart disease 1 10.5 GAS5 HOTTIP MIR221 MIR222
37 pancreatic ductal adenocarcinoma 10.5 MIR146A MIR221 HOTTIP HOTAIR
38 hyperparathyroidism 10.4
39 primary hyperparathyroidism 10.4
40 small cell cancer of the lung 10.4 HOTAIR HOTTIP NKX2-1
41 familial adenomatous polyposis 10.4
42 osteogenic sarcoma 10.4 HULC HOTTIP HOTAIR GAS5 BANCR
43 oral squamous cell carcinoma 10.4 HOTAIR MIR146A MIR221
44 leukemia, acute myeloid 10.4 HOTAIR MIR146A MIR221 MIR222
45 nasopharyngeal carcinoma 10.3 GAS5 HOTAIR HULC LINC-ROR
46 langerhans cell histiocytosis 10.3
47 histiocytosis 10.3
48 adamantinoma of long bones 10.3 LINC-ROR HULC HOTTIP HOTAIR GAS5 BRAF
49 nodular goiter 10.3
50 follicular adenoma 10.3

Graphical network of the top 20 diseases related to Thyroid Cancer, Nonmedullary, 1:



Diseases related to Thyroid Cancer, Nonmedullary, 1
Sources

Symptoms & Phenotypes for Thyroid Cancer, Nonmedullary, 1

About this section

Human phenotypes related to Thyroid Cancer, Nonmedullary, 1:

33
# Description HPO Frequency HPO Source Accession
1 goiter 33 HP:0000853
2 papillary thyroid carcinoma 33 HP:0002895
3 non-medullary thyroid carcinoma 33 HP:0040198

Symptoms via clinical synopsis from OMIM:

58
Neoplasia:
nonmedullary thyroid carcinoma (papillary)
goiter, multinodular

Clinical features from OMIM:

188550
Sources

Drugs & Therapeutics for Thyroid Cancer, Nonmedullary, 1

About this section

Drugs for Thyroid Cancer, Nonmedullary, 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 146)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Iodine Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 7553-56-2 807
2 Anti-Infective Agents, Local Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
3 Anti-Infective Agents Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
4 Hormones Phase 3,Phase 2,Phase 1,Not Applicable
5 cadexomer iodine Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
6 Nutrients Phase 2, Phase 3,Phase 3,Phase 1
7 Trace Elements Phase 2, Phase 3,Phase 3,Phase 1
8 Micronutrients Phase 2, Phase 3,Phase 3,Phase 1
9 Hormone Antagonists Phase 3,Phase 2
10 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2
11
Rosiglitazone Approved, Investigational Phase 2,Phase 1 122320-73-4 77999
12
Sirolimus Approved, Investigational Phase 2 53123-88-9 46835353 6436030 5284616
13
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
14
Everolimus Approved Phase 2 159351-69-6 6442177 70789204
15
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
16
Parathyroid hormone Approved, Investigational Phase 2,Phase 1 9002-64-6
17
Indinavir Approved Phase 2 150378-17-9 5362440
18
Azacitidine Approved, Investigational Phase 2,Phase 1 320-67-2 9444
19
Decitabine Approved, Investigational Phase 2 2353-33-5 451668
20
Vemurafenib Approved Phase 2 918504-65-1 23252090 42611257
21
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
22
Bortezomib Approved, Investigational Phase 2,Phase 1 179324-69-7 387447 93860
23
Calcium Carbonate Approved, Investigational Phase 2 471-34-1
24
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
25
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
26
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
27
Vorinostat Approved, Investigational Phase 2 149647-78-9 5311
28
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
29
Gefitinib Approved, Investigational Phase 2,Not Applicable 184475-35-2 123631
30
Aldesleukin Approved Phase 2 85898-30-2, 110942-02-4
31
Sargramostim Approved, Investigational Phase 2 123774-72-1, 83869-56-1
32
Sodium Citrate Approved, Investigational Phase 2 68-04-2
33
Tamoxifen Approved Phase 2 10540-29-1 2733526
34
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
35
Cisplatin Approved Phase 2 15663-27-1 441203 84093 2767
36
Dabrafenib Approved, Investigational Phase 2,Phase 1,Not Applicable 1195765-45-7 44462760 44516822
37
Lenvatinib Approved, Investigational Phase 2 417716-92-8
38
Salmon Calcitonin Approved, Investigational Phase 2 47931-85-1 16129616
39
Crizotinib Approved Phase 2 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
40
Pembrolizumab Approved Phase 2 1374853-91-4
41
Trametinib Approved Phase 2 871700-17-3 11707110
42
Lenalidomide Approved Phase 1, Phase 2 191732-72-6 216326
43
Durvalumab Approved, Investigational Phase 2 1428935-60-7
44
Ergocalciferol Approved, Nutraceutical Phase 2 50-14-6 5280793
45
Vitamin D Approved, Nutraceutical, Vet_approved Phase 2 1406-16-2
46
Alfacalcidol Approved, Nutraceutical Phase 2 41294-56-8 5282181
47
Calcium Approved, Nutraceutical Phase 2 7440-70-2 271
48
Citric Acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
49
SB-649868 Experimental, Investigational Phase 2,Phase 1 110-16-7, 110-17-8 444972
50
Doxil Approved June 1999 Phase 2 31703

Interventional clinical trials:

(show top 50) (show all 120)
# Name Status NCT ID Phase Drugs
1 Decision Making on Radioactive Iodine Treatment for Papillary Thyroid Cancer Completed NCT01083550 Phase 2, Phase 3
2 Lateral Neck Sentinel Lymph Node Biopsy(LSLNB)in PTC Completed NCT01137097 Phase 2, Phase 3
3 Prophylactic Central Lymph Node Dissection in Papillary Thyroid Microcarcinoma Completed NCT00795782 Phase 3
4 A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen. Completed NCT00295763 Phase 3 Thyrogen (thyrotropin alfa for injection)
5 Extent of Central Lymph Node Dissection in Papillary Thyroid Microcarcinoma Recruiting NCT01149161 Phase 2, Phase 3
6 IoN- Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients Recruiting NCT01398085 Phase 2, Phase 3
7 A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior VEGFR-targeted Therapy Recruiting NCT03690388 Phase 3 Cabozantinib;Placebo
8 High Dose vs Low Dose I 131 +/- rhTSH for Differentiated Thyroid Cancer Active, not recruiting NCT00415233 Phase 3
9 ESTIMation of the ABiLity of Prophylactic Central Compartment Neck Dissection to Modify Outcomes in Low-risk Differentiated Thyroid Cancer Not yet recruiting NCT03570021 Phase 3
10 Rosiglitazone in Treating Patients With Locoregionally Extensive or Metastatic Thyroid Cancer Unknown status NCT00098852 Phase 2 rosiglitazone maleate
11 Everolimus in Treating Patients With Progressive or Recurrent, Unresectable, or Metastatic Thyroid Cancer Unknown status NCT01118065 Phase 2 everolimus
12 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
13 Selumetinib in Treating Patients With Papillary Thyroid Cancer That Did Not Respond to Radioactive Iodine Completed NCT00559949 Phase 2 Selumetinib
14 Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131 Completed NCT00085293 Phase 2 Decitabine
15 A Study of Vemurafenib (RO5185426) in Participants With Metastatic or Unresectable Papillary Thyroid Cancer Positive for the BRAF V600 Mutation Completed NCT01286753 Phase 2 Vemurafenib
16 Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer Completed NCT01502410 Phase 2 sorafenib tosylate
17 Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy Completed NCT00104871 Phase 2 Bortezomib
18 Prevention of Hypocalcemia in Patients Undergoing Total Thyroidectomy Plus Central Neck Dissection Completed NCT00630214 Phase 2
19 Sutent Adjunctive Treatment of Differentiated Thyroid Cancer Completed NCT00668811 Phase 2 SU011248, Sutent
20 A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H... Completed NCT00923481 Phase 2 Fostamatinib disodium
21 A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers Completed NCT01524978 Phase 2 cetuximab;vemurafenib;vemurafenib
22 Romidepsin in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Has Not Responded to Radioactive Iodine Completed NCT00098813 Phase 2 romidepsin
23 Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer Completed NCT00118248 Phase 2 tanespimycin
24 Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy Completed NCT00729157 Phase 2
25 Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer Completed NCT01811212 Phase 2 Cabozantinib S-malate
26 Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer Completed NCT00519896 Phase 2 sunitinib malate
27 Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid Cancer Completed NCT00134043 Phase 2 vorinostat
28 Thalidomide in Treating Patients With Thyroid Cancer Completed NCT00026533 Phase 2 thalidomide
29 Celecoxib in Treating Patients With Progressive Metastatic Differentiated Thyroid Cancer Completed NCT00061906 Phase 2 celecoxib
30 Everolimus in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer Completed NCT01164176 Phase 2 everolimus
31 Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy Completed NCT00095836 Phase 2 Gefitinib
32 A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid Cancer Completed NCT00121628 Phase 2 AMG 706
33 Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors Completed NCT00019331 Phase 2 DetoxPC
34 Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
35 Central Neck Dissection in Patients With Clinical Node Negative Thyroid Cancer Recruiting NCT02138214 Phase 2
36 Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer Recruiting NCT03630120 Phase 2 Lenvatinib;Sorafenib;Cabozantinib;Vandetanib
37 Lenvatinib and Iodine Therapy in Treating Patients With Radioactive Iodine-Sensitive Differentiated Thyroid Cancer Recruiting NCT03506048 Phase 2 Lenvatinib
38 A Study of Oral LOXO-292 in Pediatric Patients With Advanced Solid or Primary Central Nervous System Tumors Recruiting NCT03899792 Phase 1, Phase 2 LOXO-292
39 Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) Recruiting NCT02568267 Phase 2 Entrectinib
40 Lenvatinib and Pembrolizumab in DTC Recruiting NCT02973997 Phase 2 Lenvatinib
41 Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer Recruiting NCT02393690 Phase 2 Selumetinib
42 Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer Recruiting NCT02152995 Phase 2 Trametinib
43 Phase 1/2 Study of LOXO-292 in Patients With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer Recruiting NCT03157128 Phase 1, Phase 2 LOXO-292
44 Total Thyroidectomy With and Without Prophylactic Central Neck Lymph Node Dissection in People With Low-risk Papillary Thyroid Cancer Active, not recruiting NCT02408887 Phase 2
45 Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer Active, not recruiting NCT01723202 Phase 2 dabrafenib;trametinib
46 Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer Active, not recruiting NCT01208051 Phase 1, Phase 2 Cediranib Maleate;Lenalidomide
47 Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery Active, not recruiting NCT00381641 Phase 2 Sunitinib Malate
48 Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer Active, not recruiting NCT01709292 Phase 2 Vemurafenib (All Groups);Vemurafenib (Post Surgery) - Group A + C
49 Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial Not yet recruiting NCT03753919 Phase 2 Durvalumab;Tremelimumab
50 Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer Terminated NCT00095693 Phase 2 sorafenib tosylate

Search NIH Clinical Center for Thyroid Cancer, Nonmedullary, 1

Sources

Genetic Tests for Thyroid Cancer, Nonmedullary, 1

About this section

Genetic tests related to Thyroid Cancer, Nonmedullary, 1:

# Genetic test Affiliating Genes
1 Papillary Thyroid Carcinoma 30
Sources

Anatomical Context for Thyroid Cancer, Nonmedullary, 1

About this section

MalaCards organs/tissues related to Thyroid Cancer, Nonmedullary, 1:

42
Thyroid, Lymph Node, Endothelial, Bone, Brain, Breast, Pituitary
Sources

Publications for Thyroid Cancer, Nonmedullary, 1

About this section

Articles related to Thyroid Cancer, Nonmedullary, 1:

(show top 50) (show all 3205)
# Title Authors Year
1
Aggressive papillary thyroid carcinoma in a child with type 2 congenital generalized lipodystrophy. ( 30864635 )
2019
2
Oncocytic and tall columnar type papillary thyroid carcinoma arising on a mature cystic teratoma: A case report and literature review. ( 30623925 )
2019
3
Ectopic Papillary Thyroid Carcinoma Mimicking Esophageal Cancer in FDG PET: A Case Report. ( 30394932 )
2019
4
Papillary thyroid carcinoma in cervical lymph nodes with vanished thyroid gland after ablation of Graves' disease by radioactive iodine. ( 30854863 )
2019
5
BRAF gene mutations in synchronous papillary thyroid carcinoma and Langerhans cell histiocytosis co-existing in the thyroid gland: a case report and literature review. ( 30795755 )
2019
6
Synchronous primary hyperparathyroidism, follicular thyroid carcinoma, and papillary thyroid carcinoma. ( 30614854 )
2019
7
Lipase member H is a downstream molecular target of hypoxia inducible factor-1α and promotes papillary thyroid carcinoma cell migration in BCPAP and KTC-1 cell lines. ( 30774423 )
2019
8
Simultaneous Hodgkin lymphoma and BRAFV600E-positive papillary thyroid carcinoma: A case report. ( 30653166 )
2019
9
Solid papillary thyroid carcinoma with Hashimoto's thyroiditis: description of a further case with challenging cytological features. ( 30659000 )
2019
10
Association Between Radiomics Signature and Disease-Free Survival in Conventional Papillary Thyroid Carcinoma. ( 30872763 )
2019
11
The immunocytochemical expression of VE-1 (BRAF V600E-related) antibody identifies the aggressive variants of papillary thyroid carcinoma on liquid-based cytology. ( 30875124 )
2019
12
Predictive factors for central lymph node and lateral cervical lymph node metastases in papillary thyroid carcinoma. ( 30879178 )
2019
13
Long noncoding RNA H19 is a critical oncogenic driver and contributes to epithelial-mesenchymal transition in papillary thyroid carcinoma. ( 30881130 )
2019
14
A thyroid gland with over 30 foci of papillary thyroid carcinoma with activating BRAF V600E mutation. ( 30884463 )
2019
15
Prediction of Lymph Node Metastasis in Patients With Papillary Thyroid Carcinoma: A Radiomics Method Based on Preoperative Ultrasound Images. ( 30890092 )
2019
16
Urinary iodine is increased in papillary thyroid carcinoma but is not altered by regional population iodine intake status: a meta-analysis and implications. ( 30890682 )
2019
17
Tumor immune microenvironment characteristics of papillary thyroid carcinoma are associated with histopathological aggressiveness and BRAF mutation status. ( 30896061 )
2019
18
Molecular Profile and Clinicopathologic Features of Follicular Variant Papillary Thyroid Carcinoma. ( 30900082 )
2019
19
Metastasis of papillary thyroid carcinoma to the thoracic spine. ( 30900985 )
2019
20
Over-expression of miR-206 decreases the Euthyrox-resistance by targeting MAP4K3 in papillary thyroid carcinoma. ( 30904818 )
2019
21
Correlations of neck ultrasound and pathology in cervical lymph node of papillary thyroid carcinoma. ( 30905261 )
2019
22
Magnetic detection of sentinel lymph node in papillary thyroid carcinoma: The MAGIC-PAT study results. ( 30905393 )
2019
23
Expression of Leptin Receptor and Effects of Leptin on Papillary Thyroid Carcinoma Cells. ( 30906321 )
2019
24
LncRNA LINC00673 inhibits p53 expression by interacting with EZH2 and DNMT1 in papillary thyroid carcinoma. ( 30915752 )
2019
25
MiR-296-5p suppresses papillary thyroid carcinoma cell growth via targeting PLK1. ( 30915753 )
2019
26
Preoperative detection of TERT promoter and BRAFV600E mutations in papillary thyroid carcinoma in high-risk thyroid nodules. ( 30916166 )
2019
27
Association between BRAF (V600E) mutation and clinicopathological features of papillary thyroid carcinoma: a Brazilian single-centre case series. ( 30916170 )
2019
28
Active Surveillance for T1bN0M0 Papillary Thyroid Carcinoma. ( 30560718 )
2019
29
MicroRNA‑509 targets PAX6 to inhibit cell proliferation and invasion in papillary thyroid carcinoma. ( 30569166 )
2019
30
Multifocality related factors in papillary thyroid carcinoma. ( 30585170 )
2019
31
miR-29a-3p inhibits growth, proliferation, and invasion of papillary thyroid carcinoma by suppressing NF-κB signaling via direct targeting of OTUB2. ( 30588107 )
2019
32
MicroRNA Expression in the Progression and Aggressiveness of Papillary Thyroid Carcinoma. ( 30591438 )
2019
33
Coexistence of a large functioning parathyroid cyst with papillary thyroid carcinoma: A case report and review of the literature. ( 30591913 )
2019
34
Downregulation of NEAT1 reverses the radioactive iodine resistance of papillary thyroid carcinoma cell via miR-101-3p/FN1/PI3K-AKT signaling pathway. ( 30596336 )
2019
35
Predictive factors for non-small-volume central lymph node metastases (more than 5 or ≥ 2 mm) in clinically node-negative papillary thyroid carcinoma. ( 30608456 )
2019
36
Long noncoding RNA cancer susceptibility candidate 2 suppresses papillary thyroid carcinoma growth by inactivating the AKT/ERK1/2 signaling pathway. ( 30609134 )
2019
37
Gene expression profiling identifies potential molecular markers of papillary thyroid carcinoma. ( 30614796 )
2019
38
Relationship between the upregulation of Notch1 signaling and the clinical characteristics of patients with papillary thyroid carcinoma in East Asia: a systematic review and meta-analysis. ( 30622441 )
2019
39
Appropriateness of the revised Japanese guidelines' risk classification for the prognosis of papillary thyroid carcinoma: a retrospective analysis of 5,845 papillary thyroid carcinoma patients. ( 30626761 )
2019
40
Role of ultrasonographic features and quantified BRAFV600E mutation in lymph node metastasis in Chinese patients with papillary thyroid carcinoma. ( 30635590 )
2019
41
Value of contrast-enhanced ultrasound combined with elastography in evaluating cervical lymph node metastasis in papillary thyroid carcinoma. ( 30637252 )
2019
42
Network Analyses of Integrated Differentially Expressed Genes in Papillary Thyroid Carcinoma to Identify Characteristic Genes. ( 30646607 )
2019
43
Cytological diagnosis of papillary thyroid carcinoma with tall cells on ThinPrep liquid-based cytology. ( 30648353 )
2019
44
lncRNA DGCR5 acts as a tumor suppressor in papillary thyroid carcinoma via sequestering miR-2861. ( 30651878 )
2019
45
Significant racial differences in the incidence and behavior of the follicular variant of papillary thyroid carcinoma. ( 30652370 )
2019
46
STAT3-induced upregulation of lncRNA ABHD11-AS1 promotes tumour progression in papillary thyroid carcinoma by regulating miR-1301-3p/STAT3 axis and PI3K/AKT signalling pathway. ( 30657221 )
2019
47
Novel TG-FGFR1 and TRIM33-NTRK1 transcript fusions in papillary thyroid carcinoma. ( 30664823 )
2019
48
Immunohistochemical analysis of matrix metalloproteinase-9 predicts papillary thyroid carcinoma prognosis. ( 30675296 )
2019
49
Expression of Vascular Endothelial Growth Factor and Its Receptors in Thyroid Nodular Hyperplasia and Papillary Thyroid Carcinoma: A Tertiary Health Care Centre Based Study ( 30678450 )
2019
50
Detection of BRAF V600E mutation in fine-needle aspiration fluid of papillary thyroid carcinoma by droplet digital PCR. ( 30682328 )
2019
Sources

Variations for Thyroid Cancer, Nonmedullary, 1

About this section

UniProtKB/Swiss-Prot genetic disease variations for Thyroid Cancer, Nonmedullary, 1:

76
# Symbol AA change Variation ID SNP ID
1 NKX2-1 p.Ala339Val VAR_075769 rs537209983

ClinVar genetic disease variations for Thyroid Cancer, Nonmedullary, 1:

6 (show all 17)
# Gene Variation Type Significance SNP ID Assembly Location
1 MSH2 NM_000251.2(MSH2): c.1706A> G (p.Glu569Gly) single nucleotide variant Uncertain significance rs786201077 GRCh38 Chromosome 2, 47471009: 47471009
2 MSH2 NM_000251.2(MSH2): c.1706A> G (p.Glu569Gly) single nucleotide variant Uncertain significance rs786201077 GRCh37 Chromosome 2, 47698148: 47698148
3 NKX2-1 NM_001079668.2(NKX2-1): c.1106C> T (p.Ala369Val) single nucleotide variant Likely benign rs537209983 GRCh37 Chromosome 14, 36986583: 36986583
4 NKX2-1 NM_001079668.2(NKX2-1): c.1106C> T (p.Ala369Val) single nucleotide variant Likely benign rs537209983 GRCh38 Chromosome 14, 36517378: 36517378
5 BRAF NM_004333.5(BRAF): c.1799T> A (p.Val600Glu) single nucleotide variant Pathogenic rs113488022 GRCh37 Chromosome 7, 140453136: 140453136
6 BRAF NM_004333.5(BRAF): c.1799T> A (p.Val600Glu) single nucleotide variant Pathogenic rs113488022 GRCh38 Chromosome 7, 140753336: 140753336
7 BRAF NM_004333.5(BRAF): c.1799T> A (p.Val600Glu) single nucleotide variant Pathogenic rs113488022 NCBI36 Chromosome 7, 140099605: 140099605
8 PCM1 NM_006197.3(PCM1): c.2935C> T (p.Gln979Ter) single nucleotide variant Uncertain significance rs1085307084 GRCh37 Chromosome 8, 17823587: 17823587
9 PCM1 NM_006197.3(PCM1): c.2935C> T (p.Gln979Ter) single nucleotide variant Uncertain significance rs1085307084 GRCh38 Chromosome 8, 17966078: 17966078
10 PALB2 NM_024675.3(PALB2): c.2147A> G (p.Asn716Ser) single nucleotide variant Uncertain significance rs148335539 GRCh37 Chromosome 16, 23641328: 23641328
11 PALB2 NM_024675.3(PALB2): c.2147A> G (p.Asn716Ser) single nucleotide variant Uncertain significance rs148335539 GRCh38 Chromosome 16, 23630007: 23630007
12 RUNX1 NM_001754.4(RUNX1): c.749G> A (p.Arg250His) single nucleotide variant Uncertain significance rs771614642 GRCh38 Chromosome 21, 34834466: 34834466
13 RUNX1 NM_001754.4(RUNX1): c.749G> A (p.Arg250His) single nucleotide variant Uncertain significance rs771614642 GRCh37 Chromosome 21, 36206763: 36206763
14 LIG4 NM_002312.3(LIG4): c.1673A> C (p.Gln558Pro) single nucleotide variant Likely pathogenic GRCh38 Chromosome 13, 108209596: 108209596
15 LIG4 NM_002312.3(LIG4): c.1673A> C (p.Gln558Pro) single nucleotide variant Likely pathogenic GRCh37 Chromosome 13, 108861944: 108861944
16 CDH1 NM_004360.5(CDH1): c.2351G> C (p.Arg784Pro) single nucleotide variant Uncertain significance GRCh38 Chromosome 16, 68829709: 68829709
17 CDH1 NM_004360.5(CDH1): c.2351G> C (p.Arg784Pro) single nucleotide variant Uncertain significance GRCh37 Chromosome 16, 68863612: 68863612

Cosmic variations for Thyroid Cancer, Nonmedullary, 1:

9 (show top 50) (show all 1180)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6961574 ZFHX3 thyroid,NS,carcinoma,papillary carcinoma c.5539C>T p.Q1847* 16:72797143-72797143 0
2 COSM7339522 ZBTB2 thyroid,NS,carcinoma,papillary carcinoma c.1012C>G p.P338A 6:151366054-151366054 0
3 COSM7339681 XPO1 thyroid,NS,carcinoma,papillary carcinoma c.1801C>G p.Q601E 2:61492121-61492121 0
4 COSM7340098 XPO1 thyroid,NS,carcinoma,papillary carcinoma c.994G>T p.E332* 2:61495508-61495508 0
5 COSM7339812 WT1 thyroid,NS,carcinoma,papillary carcinoma c.494C>G p.S165W 11:32428568-32428568 0
6 COSM6954354 VTCN1 thyroid,NS,carcinoma,papillary carcinoma c.399C>G p.I133M 1:117156620-117156620 0
7 COSM17721 VHL thyroid,NS,carcinoma,papillary carcinoma c.241C>T p.P81S 3:10142088-10142088 0
8 COSM26416 TSHR thyroid,NS,carcinoma,papillary carcinoma c.1867G>T p.A623S 14:81143925-81143925 0
9 COSM26497 TSHR thyroid,NS,carcinoma,papillary carcinoma c.1915C>T p.P639S 14:81143973-81143973 0
10 COSM26449 TSHR thyroid,NS,carcinoma,papillary carcinoma c.1358T>C p.M453T 14:81143416-81143416 0
11 COSM26417 TSHR thyroid,NS,carcinoma,papillary carcinoma c.1868C>T p.A623V 14:81143926-81143926 0
12 COSM26419 TSHR thyroid,NS,carcinoma,papillary carcinoma c.1897G>T p.D633Y 14:81143955-81143955 0
13 COSM7340068 TSHR thyroid,NS,carcinoma,papillary carcinoma c.572C>T p.S191L 14:81096665-81096665 0
14 COSM7339928 TSC2 thyroid,NS,carcinoma,papillary carcinoma c.4760G>A p.C1587Y 16:2086290-2086290 0
15 COSM6918838 TSC2 thyroid,NS,carcinoma,papillary carcinoma c.4468G>C p.E1490Q 16:2084690-2084690 0
16 COSM7340474 TSC2 thyroid,NS,carcinoma,papillary carcinoma c.4433A>T p.D1478V 16:2084655-2084655 0
17 COSM7340359 TRRAP thyroid,NS,carcinoma,papillary carcinoma c.7672A>C p.T2558P 7:98971853-98971853 0
18 COSM7340196 TP53BP1 thyroid,NS,carcinoma,papillary carcinoma c.910G>T p.E304* 15:43477623-43477623 0
19 COSM7340198 TP53BP1 thyroid,NS,carcinoma,papillary carcinoma c.5465G>T p.G1822V 15:43409017-43409017 0
20 COSM10659 TP53 thyroid,NS,carcinoma,papillary carcinoma c.817C>T p.R273C 17:7673803-7673803 0
21 COSM10704 TP53 thyroid,NS,carcinoma,papillary carcinoma c.844C>T p.R282W 17:7673776-7673776 0
22 COSM43951 TP53 thyroid,NS,carcinoma,papillary carcinoma c.643A>G p.S215G 17:7674888-7674888 0
23 COSM11196 TP53 thyroid,NS,carcinoma,papillary carcinoma c.734G>T p.G245V 17:7674229-7674229 0
24 COSM10648 TP53 thyroid,NS,carcinoma,papillary carcinoma c.524G>A p.R175H 17:7675088-7675088 0
25 COSM43723 TP53 thyroid,NS,carcinoma,papillary carcinoma c.398T>C p.M133T 17:7675214-7675214 0
26 COSM10662 TP53 thyroid,NS,carcinoma,papillary carcinoma c.743G>A p.R248Q 17:7674220-7674220 0
27 COSM10758 TP53 thyroid,NS,carcinoma,papillary carcinoma c.659A>G p.Y220C 17:7674872-7674872 0
28 COSM5444226 TP53 thyroid,NS,carcinoma,papillary carcinoma c.96+1G>C p.? 17:7676381-7676381 0
29 COSM44225 TP53 thyroid,NS,carcinoma,papillary carcinoma c.859G>A p.E287K 17:7673761-7673761 0
30 COSM10739 TP53 thyroid,NS,carcinoma,papillary carcinoma c.481G>A p.A161T 17:7675131-7675131 0
31 COSM10654 TP53 thyroid,NS,carcinoma,papillary carcinoma c.637C>T p.R213* 17:7674894-7674894 0
32 COSM44922 TP53 thyroid,NS,carcinoma,papillary carcinoma c.670G>T p.E224* 17:7674861-7674861 0
33 COSM44338 TP53 thyroid,NS,carcinoma,papillary carcinoma c.845G>A p.R282Q 17:7673775-7673775 0
34 COSM44101 TP53 thyroid,NS,carcinoma,papillary carcinoma c.417G>C p.K139N 17:7675195-7675195 0
35 COSM10812 TP53 thyroid,NS,carcinoma,papillary carcinoma c.722C>T p.S241F 17:7674241-7674241 0
36 COSM10660 TP53 thyroid,NS,carcinoma,papillary carcinoma c.818G>A p.R273H 17:7673802-7673802 0
37 COSM10667 TP53 thyroid,NS,carcinoma,papillary carcinoma c.646G>A p.V216M 17:7674885-7674885 0
38 COSM11183 TP53 thyroid,NS,carcinoma,papillary carcinoma c.799C>T p.R267W 17:7673821-7673821 0
39 COSM43801 TP53 thyroid,NS,carcinoma,papillary carcinoma c.716A>C p.N239T 17:7674247-7674247 0
40 COSM43980 TP53 thyroid,NS,carcinoma,papillary carcinoma c.691A>G p.T231A 17:7674272-7674272 0
41 COSM10863 TP53 thyroid,NS,carcinoma,papillary carcinoma c.833C>T p.P278L 17:7673787-7673787 0
42 COSM11114 TP53 thyroid,NS,carcinoma,papillary carcinoma c.528C>G p.C176W 17:7675084-7675084 0
43 COSM44988 TP53 thyroid,NS,carcinoma,papillary carcinoma c.374C>T p.T125M 17:7675995-7675995 0
44 COSM10705 TP53 thyroid,NS,carcinoma,papillary carcinoma c.586C>T p.R196* 17:7674945-7674945 0
45 COSM10731 TP53 thyroid,NS,carcinoma,papillary carcinoma c.707A>G p.Y236C 17:7674256-7674256 0
46 COSM10735 TP53 thyroid,NS,carcinoma,papillary carcinoma c.638G>A p.R213Q 17:7674893-7674893 0
47 COSM10771 TP53 thyroid,NS,carcinoma,papillary carcinoma c.749C>T p.P250L 17:7674214-7674214 0
48 COSM10738 TP53 thyroid,NS,carcinoma,papillary carcinoma c.542G>A p.R181H 17:7675070-7675070 0
49 COSM44310 TP53 thyroid,NS,carcinoma,papillary carcinoma c.738G>A p.M246I 17:7674225-7674225 0
50 COSM11089 TP53 thyroid,NS,carcinoma,papillary carcinoma c.584T>C p.I195T 17:7674947-7674947 0

Copy number variations for Thyroid Cancer, Nonmedullary, 1 from CNVD:

7 (show all 16)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13343 1 1 124300000 Chromosomal rearrang ement Papillary thyroid carcinoma
2 13804 1 1 60900000 Chromosomal rearrang ement Papillary thyroid carcinoma
3 19995 1 152394403 152431233 Translate TPM3 Papillary thyroid carcinoma
4 42899 10 42100000 53300000 Chromosomal rearrang ement Papillary thyroid carcinoma
5 44673 10 61218526 61336824 Translate D10S170 Papillary thyroid carcinoma
6 91970 15 37900000 47600000 Copy number FGF7 Papillary thyroid carcinoma
7 95418 15 76100000 86900000 Copy number AKAP13 Papillary thyroid carcinoma
8 96732 15 92330402 92376057 Translate GOLGA5 Papillary thyroid carcinoma
9 106730 17 1 11200000 Copy number TRE2 Papillary thyroid carcinoma
10 140387 2 197100000 209100000 Copy number TRAK2 Papillary thyroid carcinoma
11 148729 2 83700000 91000000 Amplification TB10 Papillary thyroid carcinoma
12 166063 3 1 14700000 Chromosomal rearrang ement Papillary thyroid carcinoma
13 166395 3 101910849 101950501 Translate TFG Papillary thyroid carcinoma
14 194280 5 139000000 143100000 Copy number EIF4EBP3 Papillary thyroid carcinoma
15 219438 7 126900000 158821424 Chromosomal rearrangement Papillary thyroid carcinoma
16 232143 8 112100000 146364022 Amplification Papillary thyroid cancer
Sources

Expression for Thyroid Cancer, Nonmedullary, 1

About this section
Search GEO for disease gene expression data for Thyroid Cancer, Nonmedullary, 1.
Sources

Pathways for Thyroid Cancer, Nonmedullary, 1

About this section

Pathways related to Thyroid Cancer, Nonmedullary, 1 according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Cell Differentiation - Index 1
10.74 MIR221 MIR222
2
miRs in Muscle Cell Differentiation 1
10.51 MIR221 MIR222
3
LncRNA-mediated mechanisms of therapeutic resistance 1
9.7 HOTAIR LINC-ROR
Sources

GO Terms for Thyroid Cancer, Nonmedullary, 1

About this section

Biological processes related to Thyroid Cancer, Nonmedullary, 1 according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of epithelial cell migration GO:0010634 9.51 MIR221 MIR222
2 positive regulation of erythrocyte differentiation GO:0045648 9.49 MIR221 MIR222
3 thyroid gland development GO:0030878 9.48 BRAF NKX2-1
4 negative regulation of cytokine production involved in inflammatory response GO:1900016 9.46 MIR221 MIR222
5 negative regulation by host of viral genome replication GO:0044828 9.43 MIR221 MIR222
6 negative regulation of leukocyte adhesion to vascular endothelial cell GO:1904995 9.4 MIR221 MIR222
7 negative regulation of cell adhesion molecule production GO:0060354 9.37 MIR221 MIR222
8 negative regulation of TRAIL-activated apoptotic signaling pathway GO:1903122 9.32 MIR221 MIR222
9 negative regulation of hematopoietic stem cell proliferation GO:1902034 9.26 MIR221 MIR222
10 positive regulation of Schwann cell migration GO:1900149 9.16 MIR221 MIR222
11 positive regulation of Schwann cell proliferation involved in axon regeneration GO:1905046 8.96 MIR221 MIR222
12 positive regulation of axon regeneration GO:0048680 8.8 BRAF MIR221 MIR222
Sources

Sources for Thyroid Cancer, Nonmedullary, 1

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....